US stock · Healthcare sector · Biotechnology
Company Logo

Rigel Pharmaceuticals, Inc.

RIGLNASDAQ

1.10

USD
-0.06
(-5.17%)
Market Closed
-2.24P/E
-4Forward P/E
-0.11P/E to S&P500
190.120MMarket CAP
- -Div Yield

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

RECENT
PRICE

1.10

P/E
RATIO

-2.24

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-0.11

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.54 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

1.34

(1.51)

(1.47)

- -

0.44

(2.57)

(1.84)

- -

- -

(3.67)

(2.94)

- -

0.02

(2.73)

(2.52)

- -

2.40

0.73

0.83

- -

0.08

(1.36)

(1.13)

- -

0.03

(1.32)

(1.18)

- -

0.08

(1.02)

(1.00)

- -

0.09

(1.04)

(0.80)

- -

0.33

(0.58)

(0.27)

- -

0.22

(0.73)

(0.81)

- -

0.04

(0.62)

(0.62)

- -

0.28

(0.44)

(0.37)

- -

0.35

(0.40)

(0.26)

- -

0.64

(0.18)

(0.32)

- -

0.88

(0.11)

0.03

- -

0.52

(0.49)

(0.40)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.04

3.50

0.03

2.84

0.07

2.89

0.00

2.69

0.07

3.19

0.04

3.73

0.05

3.86

0.01

2.39

0.00

1.46

0.01

1.03

0.01

0.58

0.00

0.80

0.01

0.68

0.01

0.32

0.01

0.20

0.00

0.18

0.00

0.12

CAPEX per share

Book Value per share

25

29

36

41

52

63

75

87

88

88

94

126

161

167

169

169

171

Comm.Shares outs.(m)

(6.7)

(0.4)

- -

(4.2)

(0.2)

- -

(5.3)

(0.2)

- -

(2.9)

(0.0)

- -

11.0

0.5

- -

(5.7)

(0.4)

- -

(6.8)

(0.5)

- -

(4.5)

(0.3)

- -

(2.8)

(0.2)

- -

(5.5)

(0.3)

- -

(3.7)

(0.2)

- -

(4.7)

(0.2)

- -

(7.7)

(0.3)

- -

(5.5)

(0.2)

- -

(13.9)

(0.4)

- -

(34.9)

(1.2)

- -

(2.2)

(0.1)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/6/22 | Q2)

Total liabilities
$131 m.

Total assets
$128 m.

Long-term debt
- -

Cash and equiv.
$27 m.

Goodwill - -

Retained earnings $(1,365) m.

Common stock 172 m. shares

Market Capitalisation
$190 m. (as of 25/9/22)

5

(1,818.3)%

2

(4,416.8)%

7

(1,251.3)%

8

(1,106.0)%

29

(179.1)%

20

(342.2)%

4

(1,775.6)%

45

(163.3)%

59

(116.5)%

109

(26.7)%

149

(8.4)%

89

(99.3)%

Revenue (m)

Operating margin

2

(86)

2

(99)

3

(89)

2

(91)

1

(51)

1

(69)

0

(78)

1

(70)

1

(67)

1

(30)

1

(18)

1

(85)

Depreciation (m)

Net profit (m)

- -

(1,810.0)%

- -

(4,392.9)%

- -

(1,245.1)%

- -

(1,101.9)%

- -

(178.1)%

- -

(339.6)%

- -

(1,739.3)%

- -

(158.3)%

- -

(112.8)%

- -

(27.4)%

(3.5)%

(12.0)%

0.2%

(104.4)%

Income tax rate

Net profit margin

239

- -

236

290

- -

289

210

- -

208

137

- -

128

95

- -

91

54

- -

55

99

- -

101

109

- -

110

61

10

54

48

30

34

91

21

30

66

- -

(4)

Working capital (m)

Long-term debt (m)

Equity (m)

(35.0)%

(33.4)%

(36.4)%

(33.2)%

(31.9)%

(34.2)%

(41.3)%

(39.4)%

(42.7)%

(64.9)%

(59.0)%

(70.9)%

(52.5)%

(39.1)%

(56.3)%

(124.6)%

(88.6)%

(125.8)%

(77.4)%

(65.5)%

(77.5)%

(63.3)%

(50.7)%

(64.1)%

(74.5)%

(45.1)%

(124.3)%

(40.8)%

(25.7)%

(87.4)%

(12.4)%

(7.4)%

(59.0)%

(110.4)%

(63.0)%

2,298.9%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

98

106

94

Receivables

10

16

15

Inventory

1

2

7

Other

9

14

7

Current assets

119

89

154

Acc. Payable

4

4

4

Debt due

- -

9

10

Other

54

29

50

Current liab.

58

41

64

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Rigel Pharmaceuticals, Inc. (US) started trading on November 3, 2000 (cik: 0001034842), operates in the Healthcare sector (Biotechnology industry), has 165 full-time employees, and is led by Mr. Raul Rodriguez. Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

261.61%

158.04%

Cash flow

-34.16%

-0.23%

Earnings

-27.51%

-12.67%

Dividends

- -

- -

Book value

-22.34%

-15.71%

Insider trading

Type

Shares

Date

Schorno Dean L

Award

81,250

09/14/22

Rodriguez Raul R

Award

300,000

09/14/22

Vance Dolly

Award

81,250

09/14/22

Rodriguez Raul R

Purchase

1,000,000

06/09/22

Kotzin Brian L.

Award

30,000

05/20/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

56

16

18

18

109

2021

81

26

22

20

149

2022

17

30

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.13

(0.10)

(0.08)

(0.11)

-0.18

2021

0.23

(0.08)

(0.12)

(0.13)

-0.11

2022

(0.16)

(0.08)

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

02/18/2021

GameStop, Twilio, Walmart: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...